



Knowing now matters.™



Alere Afinion™ Lipid Panel

Simple. Fast. Reliable.

Alere Afinion™ Lipid Panel supports the early diagnosis and management of patients at high risk of developing cardiovascular disease (CVD). Specifically designed to be used at the point of care, the Alere Afinion Lipid Panel can enhance clinical decision making within the timeframe of the consultation, catering to the health empowered individual.

- Quantitative determination of Total Cholesterol, HDL, LDL, Triglycerides, non-HDL and Chol/HDL ratio
- Laboratory-quality results in 8 minutes
- 15 µL capillary or venous whole blood sample, serum or plasma
- All in one test cartridge
- No sample preparation
- No manual calibration or maintenance requirements
- Ready to use liquid controls
- Connectivity solutions available



In your everyday practice, can you complete a cardiovascular risk assessment in one patient visit?

Alere Afinion Lipid Panel Test

3-step procedure

1



Draw a small volume of sample into the sampling device.

2



Insert the sampling device into the test cartridge.

3



Place the cartridge into the analyzer. The result is displayed within minutes.

Measurement of blood lipids is important

The importance of measuring blood lipids to determine the absolute risk of a cardiovascular disease is well established¹⁻⁴. The recommended time in which to check lipids is dependent on the patient's assessed probability of a cardiovascular event occurring within a five-year period^{1,2}.

Guidelines for the management of absolute cardiovascular disease risk

Guidelines for the management of absolute cardiovascular disease risk, provide direction on the management of CVD risk in a primary prevention setting. Adults should have blood lipids assessed starting at age 45 years (35 years for Aboriginal and Torres Strait Islander adults). Lipid levels should be interpreted in the context of an absolute cardiovascular risk assessment¹. In the event of a coronary heart disease (CHD) diagnosis, it is recommended that the patient be screened for diabetes and renal impairment³.

Ordering Information

Catalogue no.	Description	Pack size
AF1116069	Alere Afinion Lipid Panel	15T
AF1116072	Alere Afinion Lipid Quality Controls	2 x 1.0 mL vials (Level I & II)
AF1116049	Alere Afinion AS100 Analyzer	Each
Other tests available		
AF1116043	Alere Afinion ACR	15T
AF1116058	Alere Afinion CRP	15T
AF1116062	Alere Afinion HbA1c	15T



References

1. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. Heart Foundation, 2012.
2. Guidelines for preventive activities in general practice, 8th edn. East Melbourne: Royal Australian College of General Practitioners, 2012.
3. National Heart Foundation of Australia and CSANZ. Reducing risk in heart disease: an expert guide to clinical practice for secondary prevention of coronary heart disease. Updated 2012.
4. Cardiovascular risk charts. Heart Foundation, 2013.

We look forward to demonstrating the Alere Afinion™ System. For more information or to schedule an on-site visit, please contact Alere.



Australia
New Zealand

au.enquiries@alere.com
nz.enquiries@alere.com

1800 622 642 Free call in AUS
0800 466 951 Free call in NZ

alere.com.au
alere.co.nz